B of A Securities Maintains Neutral on Beta Bionics, Lowers Price Target to $11
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Travis Steed maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and lowers the price target from $23 to $11.
B of A Securities analyst Travis Steed maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and lowers the price target from $23 to $11.